cb2 antagonist 6 iodo 2 methyl 1 Search Results


cb2 receptor antagonist 6 iodo 2 methyl 1  (Tocris)
96
Tocris cb2 receptor antagonist 6 iodo 2 methyl 1
Cb2 Receptor Antagonist 6 Iodo 2 Methyl 1, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/AM+630/pmc03753184-127-25-34
Average 96 stars, based on 1 article reviews
cb2 receptor antagonist 6 iodo 2 methyl 1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
cb2 antagonist 6 iodo 2 methyl 1  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology cb2 antagonist 6 iodo 2 methyl 1
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), <t>CB2</t> (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Cb2 Antagonist 6 Iodo 2 Methyl 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/AM-630/pmc11661628-202-14-18
Average 92 stars, based on 1 article reviews
cb2 antagonist 6 iodo 2 methyl 1 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
cb2 antagonist 6 iodo 2 methyl 1  (Tocris)
96
Tocris cb2 antagonist 6 iodo 2 methyl 1
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), <t>CB2</t> (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Cb2 Antagonist 6 Iodo 2 Methyl 1, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/AM+630/10__1097_slash_aln__0b013e3181a51e0d-45-11-19
Average 96 stars, based on 1 article reviews
cb2 antagonist 6 iodo 2 methyl 1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
1341  (Bio-Techne corporation)
93
Bio-Techne corporation 1341
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), <t>CB2</t> (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
1341, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/1341/custom%401341%4030186120
Average 93 stars, based on 1 article reviews
1341 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
trpv4 antagonist 2 methyl  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology trpv4 antagonist 2 methyl
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), <t>TRPV4</t> (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Trpv4 Antagonist 2 Methyl, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/HC+067047/pmc11661628-202-48-53
Average 93 stars, based on 1 article reviews
trpv4 antagonist 2 methyl - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
benzoic acid  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology benzoic acid
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), <t>TRPV4</t> (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Benzoic Acid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/Benzoic+acid/pm39705234-202-47-56
Average 94 stars, based on 1 article reviews
benzoic acid - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
trpv4 agonist n  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology trpv4 agonist n
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), <t>TRPV4</t> (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Trpv4 Agonist N, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/GSK1016790A/pmc11661628-202-57-63
Average 93 stars, based on 1 article reviews
trpv4 agonist n - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
cb1 antagonist 1  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology cb1 antagonist 1
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the <t>CB1</t> (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Cb1 Antagonist 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/AM-251/pmc11661628-202-8-18
Average 92 stars, based on 1 article reviews
cb1 antagonist 1 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
anandamide aea  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anandamide aea
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the <t>CB1</t> (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Anandamide Aea, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/Anandamide/pm39705234-202-78-80
Average 93 stars, based on 1 article reviews
anandamide aea - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
cannabinoid receptor 2 cb2r antagonist 6 iodopravadoline  (TargetMol)
94
TargetMol cannabinoid receptor 2 cb2r antagonist 6 iodopravadoline
The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the <t>CB1</t> (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).
Cannabinoid Receptor 2 Cb2r Antagonist 6 Iodopravadoline, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cb2+antagonist+6+iodo+2+methyl+1/6-Iodopravadoline/pm39426255-61-1-12
Average 94 stars, based on 1 article reviews
cannabinoid receptor 2 cb2r antagonist 6 iodopravadoline - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Journal: PLOS ONE

Article Title: Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro , acting as potential multi-step inhibitors of atherosclerosis development

doi: 10.1371/journal.pone.0310777

Figure Lengend Snippet: The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Article Snippet: The following cannabinoid receptor ligands were used: the CB1 antagonist 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251) and the CB2 antagonist 6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630) (Santa Cruz Biotechnology), the TRPV-1 antagonist 2E-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide (AMG9810) (ABCAM), the TRPV-1 agonist 8-methyl-N-vanillyl-6-nonenamide or capsaicin (ABCAM), the GPR55 agonist 3-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-N,N-dimethyl-4-(1-pyrrolidinyl) benzenesulfonamide (ML184, Sigma-Aldrich), the GPR55 antagonist 4-[4,6-dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid (CID16020046), the TRPV4 antagonist 2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N -[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide (HC067047) (Santa Cruz Biotech.), the TRPV4 agonist N-[(1S)-1-[[4-[(2S)-2-[[(2,4-dichlorophenyl) sulfonyl]amine]-3-hydroxy-1-oxopropyl]-1-piperazinyl]carbonyl]-3-methylbutyl]benzo [b]thiophene-2-carboxamide (GSK1016790A) (Santa Cruz Biotech.), the endocannabinoid and CB1 and CB2 agonist N-arachidonoylethanolamine or anandamide (AEA) (Santa Cruz Biotechnology).

Techniques: Incubation

The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Journal: PLOS ONE

Article Title: Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro , acting as potential multi-step inhibitors of atherosclerosis development

doi: 10.1371/journal.pone.0310777

Figure Lengend Snippet: The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Article Snippet: The following cannabinoid receptor ligands were used: the CB1 antagonist 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251) and the CB2 antagonist 6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630) (Santa Cruz Biotechnology), the TRPV-1 antagonist 2E-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide (AMG9810) (ABCAM), the TRPV-1 agonist 8-methyl-N-vanillyl-6-nonenamide or capsaicin (ABCAM), the GPR55 agonist 3-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-N,N-dimethyl-4-(1-pyrrolidinyl) benzenesulfonamide (ML184, Sigma-Aldrich), the GPR55 antagonist 4-[4,6-dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid (CID16020046), the TRPV4 antagonist 2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N -[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide (HC067047) (Santa Cruz Biotech.), the TRPV4 agonist N-[(1S)-1-[[4-[(2S)-2-[[(2,4-dichlorophenyl) sulfonyl]amine]-3-hydroxy-1-oxopropyl]-1-piperazinyl]carbonyl]-3-methylbutyl]benzo [b]thiophene-2-carboxamide (GSK1016790A) (Santa Cruz Biotech.), the endocannabinoid and CB1 and CB2 agonist N-arachidonoylethanolamine or anandamide (AEA) (Santa Cruz Biotechnology).

Techniques: Incubation

The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Journal: PLOS ONE

Article Title: Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro , acting as potential multi-step inhibitors of atherosclerosis development

doi: 10.1371/journal.pone.0310777

Figure Lengend Snippet: The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Article Snippet: The following cannabinoid receptor ligands were used: the CB1 antagonist 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251) and the CB2 antagonist 6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630) (Santa Cruz Biotechnology), the TRPV-1 antagonist 2E-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide (AMG9810) (ABCAM), the TRPV-1 agonist 8-methyl-N-vanillyl-6-nonenamide or capsaicin (ABCAM), the GPR55 agonist 3-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-N,N-dimethyl-4-(1-pyrrolidinyl) benzenesulfonamide (ML184, Sigma-Aldrich), the GPR55 antagonist 4-[4,6-dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid (CID16020046), the TRPV4 antagonist 2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N -[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide (HC067047) (Santa Cruz Biotech.), the TRPV4 agonist N-[(1S)-1-[[4-[(2S)-2-[[(2,4-dichlorophenyl) sulfonyl]amine]-3-hydroxy-1-oxopropyl]-1-piperazinyl]carbonyl]-3-methylbutyl]benzo [b]thiophene-2-carboxamide (GSK1016790A) (Santa Cruz Biotech.), the endocannabinoid and CB1 and CB2 agonist N-arachidonoylethanolamine or anandamide (AEA) (Santa Cruz Biotechnology).

Techniques: Incubation

The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Journal: PLOS ONE

Article Title: Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro , acting as potential multi-step inhibitors of atherosclerosis development

doi: 10.1371/journal.pone.0310777

Figure Lengend Snippet: The cells were incubated for 24 h with oxLDL (10 μg mL -1 ) without (-) or with E1 (2 μg mL -1 ), E2 (5 μg mL -1 ) and E3 (5 μg mL -1 ), in the absence (-) and the presence (+) of the antagonists of the CB1 (AM251, 5 μM) ( A ), CB2 (AM630, 5 μM) ( B ), TRPV1 (AMG9810, AMG, 5 μM) ( C ), TRPV4 (HC067047, HC, 10 μM) ( E ) and GPR55 (CID160246, CID, 8 μM) ( G ). The effect of the agonists of the TRPV1 (capsaicin, Cap, 50 μM) ( D ), TRPV4 (GSK1016790A, GSK, 10 μM) ( F ) and GPR55 (ML184, ML, 10 μM) ( H ) were also tested but with incubations for 6 h. The results are presented as mean and SD from three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test was used to compare the condition with the extract alone and the same extract plus antagonist or agonist (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001).

Article Snippet: The following cannabinoid receptor ligands were used: the CB1 antagonist 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251) and the CB2 antagonist 6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630) (Santa Cruz Biotechnology), the TRPV-1 antagonist 2E-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide (AMG9810) (ABCAM), the TRPV-1 agonist 8-methyl-N-vanillyl-6-nonenamide or capsaicin (ABCAM), the GPR55 agonist 3-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-N,N-dimethyl-4-(1-pyrrolidinyl) benzenesulfonamide (ML184, Sigma-Aldrich), the GPR55 antagonist 4-[4,6-dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid (CID16020046), the TRPV4 antagonist 2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N -[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide (HC067047) (Santa Cruz Biotech.), the TRPV4 agonist N-[(1S)-1-[[4-[(2S)-2-[[(2,4-dichlorophenyl) sulfonyl]amine]-3-hydroxy-1-oxopropyl]-1-piperazinyl]carbonyl]-3-methylbutyl]benzo [b]thiophene-2-carboxamide (GSK1016790A) (Santa Cruz Biotech.), the endocannabinoid and CB1 and CB2 agonist N-arachidonoylethanolamine or anandamide (AEA) (Santa Cruz Biotechnology).

Techniques: Incubation